STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy

STRM.BIO (DNA) was awarded an ARPA-H EMBODY contract on Dec 3, 2025 with up to $8.4 million to support a first-phase program advancing its proprietary megakaryocyte-derived extracellular vesicle (MV) delivery platform for in vivo cell and gene therapy.

Rhea-AI Summary

STRM.BIO (DNA) was awarded an ARPA-H EMBODY contract on Dec 3, 2025 with up to $8.4 million to support a first-phase program advancing its proprietary megakaryocyte-derived extracellular vesicle (MV) delivery platform for in vivo cell and gene therapy.

STRM.BIO will act as prime, partnering with Ginkgo (DNA), the University of British Columbia, and Advanced Bioprocess Services to develop bone marrow-targeted in vivo CAR-T therapeutics using MV delivery and self-amplifying RNA expertise.

Positive

• ARPA-H award up to $8.4 million
• STRM.BIO named prime awardee leading the project
• Collaboration includes Ginkgo (DNA), UBC, and ABS
• Program targets bone marrow in vivo delivery for CAR-T

Negative

• Funding covers only the first phase of the project

Argus Dec 3 session

+4.89% close to close Open Argus

Details

News Market Reaction – DNA

On Dec 3, the day this news came out, DNA closed 4.89% above the previous close.

Data tracked by StockTitan Argus for the Dec 3 session.

Market Context

This announcement highlights Ginkgo Bioworks’ role as a technology partner in STRM.BIO’s ARPA‑H EMBO...

Analysis

This announcement highlights Ginkgo Bioworks’ role as a technology partner in STRM.BIO’s ARPA‑H EMBODY contract, contributing RNA construct design and immune cell engineering to in vivo CAR‑T development. It follows other agency-funded collaborations, including BARDA and DOE-linked projects, reinforcing a strategy built around externally financed R&D. Investors may watch how these programs translate into recurring revenue, monitor future use of the existing S-3 shelf and 424B5 pathway, and track any further insider activity or major program milestones.

Key Figures

ARPA-H EMBODY funding: $8.4 million Q3 2025 total revenue: $39M Q3 2025 GAAP net loss: $81M +5 more

ARPA-H EMBODY funding

$8.4 million

First phase funding for STRM.BIO MV platform project

Q3 2025 total revenue

$39M

Quarter ended September 30, 2025

Q3 2025 GAAP net loss

$81M

Quarter ended September 30, 2025

Cash & securities

$462M

As of September 30, 2025

Full-year 2025 revenue guidance

$167–$187M

Company reaffirmed guidance

BARDA project value

$22.2M

BioMaP-Consortium filovirus mAb project

DOE phenotyping contract

$47M

Four-year contract upper value with PNNL/EMSL

52-week range

$5.00–$17.58

Price was 43.69% below high, 98% above low pre-news

Historical Context

5 past events · Latest: Dec 09

5 events

1. Dec 09

   ARPA-H partnership

   24h Move

   +1.7%

   ARPA-H funded CATALYST project to build drug safety prediction platform.

2. Dec 05

   Government contract

   24h Move

   +0.4%

   Up to $47M DOE-linked contract to build high-throughput phenotyping platform.

3. Dec 03

   ARPA-H EMBODY award

   24h Move

   +4.9%

   ARPA-H EMBODY contract with up to $8.4M backing STRM.BIO MV delivery program.

4. Nov 06

   Q3 2025 earnings

   24h Move

   -2.5%

   Revenue decline and net loss of $81M despite reaffirmed 2025 guidance.

5. Nov 03

   BARDA project award

   24h Move

   -1.5%

   BARDA BioMaP agreement up to $22.2M for filovirus mAb manufacturing work.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-viral delivery technologies, in vivo, extracellular vesicle, megakaryocyte-derived, +4 more

8 terms

non-viral delivery technologies medical

"pioneering non-viral delivery technologies for in vivo cell and gene therapy"

Non-viral delivery technologies are methods for getting therapeutic material (like DNA, RNA or proteins) into cells without using modified viruses, using tools such as tiny fat-based particles, synthetic carriers, or physical techniques. For investors, they matter because they can reduce safety risks, simplify manufacturing and enable repeat dosing—think of choosing a reliable delivery truck over a living courier—which can lower development costs and broaden potential markets.

in vivo medical

"non-viral delivery technologies for in vivo cell and gene therapy"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

extracellular vesicle medical

"megakaryocyte-derived extracellular vesicle (MV) delivery platform for in vivo"

Tiny, membrane-bound particles that cells release to carry proteins, genetic material and other molecules to nearby or distant cells; think of them as sealed biological messages or parcels sent by cells. They matter to investors because they are being developed as new diagnostic markers, drug-delivery systems and therapeutic products — a platform technology with potential for recurring revenue, partnerships, and regulatory milestones that can drive company value.

megakaryocyte-derived medical

"developing and leveraging STRM's proprietary megakaryocyte-derived extracellular"

Something described as megakaryocyte-derived comes from megakaryocytes, the large bone-marrow cells that act like factories producing platelets and related particles found in the bloodstream. Investors should care because therapies, diagnostics or safety signals tied to these products indicate how a drug or test interacts with blood production and clotting processes—similar to tracking whether a factory’s parts meet quality standards, which affects product performance and regulatory risk.

CAR-T medical

"to develop in vivo CAR-T therapeutics. The partnership will leverage"

CAR-T is a type of cancer therapy that reprograms a patient’s own immune cells to seek and destroy specific cancer cells, like teaching guard dogs a new scent to track intruders. It matters to investors because CAR-T treatments can command high prices, drive strong revenue for successful developers, and carry regulatory and manufacturing risks that can sharply affect a company’s valuation and long-term growth prospects.

self-amplifying RNA medical

"UBC's expertise in the design and biology of self-amplifying RNA (saRNA)"

Self-amplifying RNA is an engineered form of genetic material that enters cells and not only instructs them to produce a target protein but also carries the ability to copy itself inside the cell, like a small factory that makes more instruction manuals. For investors, it matters because this self-replicating feature can enable lower doses, smaller manufacturing runs and potentially faster or cheaper development of vaccines and treatments, affecting clinical timelines, cost structures and commercial prospects.

saRNA medical

"design and biology of self-amplifying RNA (saRNA), and ABS's expertise"

Sarna is the Spanish and Portuguese word for scabies, a contagious skin infestation caused by tiny mites that burrow into the skin and trigger intense itching, rashes and sleep disruption—think of it as similar to head lice but affecting the skin surface. It matters to investors because demand for effective treatments, diagnostics and public‑health measures creates a clearly defined market; regulatory approvals, clinical trial results and treatment uptake can directly affect healthcare costs, company revenues and valuations.

gene therapy medical

"delivery technologies for in vivo cell and gene therapy, today announced"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has been awarded a contract from the Advanced Research Projects Agency for Health (ARPA-H) through its Engineering of Immune Cells Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The award includes up to $8.4 million in funding to support the first phase of this project, focused on developing and leveraging STRM's proprietary megakaryocyte-derived extracellular vesicle (MV) delivery platform for in vivo immune cell engineering.

STRM.BIO's MV platform represents a novel, cell-derived delivery modality with the potential to overcome many of the key barriers limiting current viral and synthetic in vivo delivery systems.

"This award marks an important milestone for STRM.BIO in our mission to unlock the potential of extracellular vesicles for in vivo cell and gene therapy," said Michael Luther, Ph.D., CEO of STRM.BIO. "Funding from ARPA-H provides us an extraordinary opportunity to accelerate the development of our MV platform and genetic medicines pipeline to enable precise, efficient, and safe delivery for complex genetic cargos directly to the bone marrow in vivo, with multiple dosing potential when needed."

STRM.BIO will act as lead for the project, bringing their novel MV platform and expertise in bone marrow-targeted in vivo delivery. As the Prime Awardee, STRM will collaborate with Ginkgo Bioworks (NYSE: DNA), the University of British Columbia (UBC), and Advanced Bioprocess Services (ABS) to develop in vivo CAR-T therapeutics. The partnership will leverage Ginkgo's expertise in RNA construct design and immune cell engineering, UBC's expertise in the design and biology of self-amplifying RNA (saRNA), and ABS's expertise in vesicle production and bioprocessing to advance the novel in vivo immune cell engineering approach.

"This funding from ARPA-H is transformative for high-impact projects like this," said David Raiser, Ph.D., COO of STRM.BIO. "We're fortunate to be able work with partners who share our vision and drive for a new generation of in vivo cell and gene therapies enabled by innovative, non-viral delivery technologies."

CEO Mike Luther further added, "The insights gained from this effort will expand the potential of our MV platform, opening new pipeline opportunities for in vivo engineering of immune and hematopoietic cells to address unmet medical needs, and advance the broader field of cell and gene therapy."

About STRM.BIO

STRM.BIO is a biotechnology company developing a novel, non-viral, cell-derived delivery modality that enables safe, targeted, and scalable in vivo delivery of genetic medicines. The company's megakaryocyte-derived vesicle (MV) technology is designed to address the challenges of traditional viral and synthetic delivery systems, unlocking new therapeutic opportunities across gene editing, RNA therapeutics, and immune cell engineering. STRM.BIO is headquartered in Cambridge, Massachusetts. Learn more at www.strm.bio.

This research was funded, in part, by the Advanced Research Projects Agency for Health (ARPA-H). The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the U.S. Government. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/strmbio-awarded-arpa-h-contract-to-advance-megakaryocyte-derived-vesicle-platform-for-in-vivo-cell-engineering-and-gene-therapy-302631703.html

SOURCE STRM.BIO

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did STRM.BIO announce on December 3, 2025 regarding ARPA-H funding for DNA?

STRM.BIO announced an ARPA-H EMBODY contract awarding up to $8.4 million to fund the first phase of its MV delivery platform program.

How will the ARPA-H award affect STRM.BIO's collaboration with Ginkgo (DNA)?

STRM.BIO will lead the program as prime awardee and collaborate with Ginkgo (DNA) on RNA construct design and immune cell engineering.

What is the focus of the STRM.BIO ARPA-H project for DNA and partners?

The project focuses on developing MV-based bone marrow-targeted in vivo CAR-T therapeutics and non-viral delivery of genetic cargos.

Who are STRM.BIO's disclosed partners on the ARPA-H EMBODY award with DNA?

Partners include Ginkgo (DNA), the University of British Columbia, and Advanced Bioprocess Services.

What does 'first phase' funding mean for STRM.BIO's program timeline and scope?

The award funds the first phase of development for the MV platform; additional phases or funding are not specified.

Will the STRM.BIO MV platform support multiple dosing according to the announcement?

Yes; the company said the MV platform aims to enable precise, efficient, and safe delivery with multiple dosing potential to bone marrow in vivo.